EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions

Yu-Fei Chen, Ying-Ying Xu, Zhi-Ming Shao, Ke-Da Yu iD

Cancer Communications · 2023-03 · 43 (3) · 297-337

DOI: 10.1002/cac2.12387 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Communications, online erschienen am 10.11.2022. Verfasst von Yu-Fei Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, P. R. China. Hauptthemen laut MEDLINE: Breast Neoplasms, Immunoconjugates, Antineoplastic Agents. Die Arbeit wurde bisher 160-mal zitiert (Crossref) und nennt 180 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody‐drug conjugates (ADCs) are a rapidly developing therapeutic approach in cancer treatment that has shown remarkable activity in breast cancer. Currently, there are two ADCs approved for the treatment of human epidermal growth factor receptor 2‐positive breast cancer, one for triple‐negative breast cancer, and multiple investigational ADCs in clinical trials. However, drug resistance has been noticed in clinical use, especially in trastuzumab emtansine. Here, the mechanisms of ADC resistance are summarized into four categories: antibody‐mediated resistance, impaired drug trafficking, disrupted lysosomal function, and payload‐related resistance. To overcome or prevent resistance to ADCs, innovative development strategies and combination therapy options are being investigated. Analyzing predictive biomarkers for optimal therapy selection may also help to prevent drug resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsImmunoconjugatesAntineoplastic AgentsHumansFemaleAdo-Trastuzumab Emtansine

Stichwörter der Autor:innen

Antibody-drug conjugatebreast cancercombination therapydrug resistancepredictive biomarker

Substanzen

ImmunoconjugatesAntineoplastic AgentsAdo-Trastuzumab Emtansine

Autor:innen und Institutionen

  • Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, P. R. China.
  • Shanghai Medical College, Fudan University, Shanghai, 200032, P. R. China.
  • Department of Breast Surgery, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, 110001, P. R. China.

ORCID-Profile: Ke-Da Yu

Zitieren

APA

Chen, Y. F., Xu, Y. Y., Shao, Z. M., & Yu, K. D. (2023). Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions. Cancer Communications, 43(3), 297-337. https://doi.org/10.1002/cac2.12387

Vancouver

Chen YF, Xu YY, Shao ZM, Yu KD. Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions. Cancer Communications. 2023;43(3):297-337. doi:10.1002/cac2.12387

BibTeX
@article{Chen2023,
  author = {Chen, Yu-Fei and Xu, Ying-Ying and Shao, Zhi-Ming and Yu, Ke-Da},
  title = {Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions},
  journal = {Cancer Communications},
  year = {2023},
  volume = {43},
  number = {3},
  pages = {297--337},
  doi = {10.1002/cac2.12387}
}
Kostenlos starten →